It is estimated that more than 100 million people suffer from chronic pain and more than 30 million people suffer from chronic itch in the U.S. Current therapeutics for chronic pain and itch are inadequate and limited by insufficient efficacy and side effects. Although itch-sensing neurons are a subset of C-fiber nociceptors in dorsal root ganglion, pain and itch are mediated via distinct neural circuits in the spinal cord. There is also crosstalk between pain and itch pathways: pain suppresses itch while analgesic such as morphine can provoke itch. Therefore it will be of great importance to develop new drugs that can target both pain and itch. Toward this goal, we have come up with a novel strategy of developing monoclonal antibodies to treat pain and itch simultaneously. We will employ a multidisciplinary approach that combines molecular biology, biochemistry, electrophysiology in isolated cells, whole DRG preparation, and spinal cord slices, and behavioral testing of pain and itch using evoked and spontaneous responses. Successful accomplishment of the project will not only provide a better understanding of the molecular and synaptic mechanisms of pain and itch sensations but also lead to new therapies for treating debilitating pain and itch conditions.

Public Health Relevance

Current treatments for debilitating chronic pain and itch conditions are limited by efficacy and side effects. We propose to develop novel monoclonal antibodies for pain and itch relief and further test the effects of these antibodies on behaviors and spinal cord synaptic transmission in mouse models of acute and chronic pain and itch. Our proposal will lead to novel therapeutics to treat pain and itch-related disease conditions and also provide new insights into synaptic mechanisms of pain and itch.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1)
Program Officer
Oshinsky, Michael L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
Chang, Wonseok; Berta, Temugin; Kim, Yong Ho et al. (2018) Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel. Neurosci Bull 34:4-12
Bang, Sangsu; Yoo, Jiho; Gong, Xingrui et al. (2018) Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies. Neurosci Bull 34:22-41
Bang, Sangsu; Xie, Ya-Kai; Zhang, Zhi-Jun et al. (2018) GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain. J Clin Invest 128:3568-3582
Liu, Tong; Han, Qingjian; Chen, Gang et al. (2016) Toll-like receptor 4 contributes to chronic itch, alloknesis, and spinal astrocyte activation in male mice. Pain 157:806-17
Taves, Sarah; Berta, Temugin; Liu, Da-Lu et al. (2016) Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord. Brain Behav Immun 55:70-81
Ji, Ru-Rong (2015) Neuroimmune interactions in itch: Do chronic itch, chronic pain, and chronic cough share similar mechanisms? Pulm Pharmacol Ther 35:81-6
Xu, Zhen-Zhong; Kim, Yong Ho; Bang, Sangsu et al. (2015) Inhibition of mechanical allodynia in neuropathic pain by TLR5-mediated A-fiber blockade. Nat Med 21:1326-31
Chen, Gang; Park, Chul-Kyu; Xie, Rou-Gang et al. (2015) Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-? secretion. J Clin Invest 125:3226-40
Taves, Sarah; Ji, Ru-Rong (2015) Itch control by Toll-like receptors. Handb Exp Pharmacol 226:135-50